查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1861784

特发性肺纤维化市场按治疗类别、给药途径、通路和最终用户划分 - 全球预测 2025-2032

Idiopathic Pulmonary Fibrosis Market by Therapeutic Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，特发性肺纤维化市场将成长至 56.6 亿美元，复合年增长率为 5.64%。

关键市场统计数据
基准年 2024 36.5亿美元
预计年份：2025年 38.6亿美元
预测年份 2032 56.6亿美元
复合年增长率 (%) 5.64%

特发性肺纤维化的临床和营运实施：重点关注诊断复杂性、治疗进展和不断发展的护理路径

特发性肺纤维化 (IPF) 是一种持续且复杂的临床挑战，需要在诊断、治疗和护理的各个方面进行协调一致的改进。由于症状特异性且常与其他慢性呼吸系统疾病重迭，临床医生在早期发现疾病方面面临诸多障碍；而确诊则需要高解析度影像检查、肺功能测试以及多学科会诊。这些诊断方面的现实情况会延迟疾病修正治疗的启动，并使疾病管理更加复杂，因此迫切需要更清晰的临床路径和更便捷的诊断资源。

同时，不断发展的治疗方法引入了缓解疾病抗纤维化药物，与传统的免疫调节疗法相辅相成，重塑了减缓纤维化进展和保护肺功能的临床范式。医疗系统目前正努力权衡新型药物的临床效益与耐受性、药物交互作用和长期依从性等因素。随着相关人员不断完善治疗流程，生物标记、个人化风险分层以及将院内专科诊疗与门诊和居家照护相结合的整合式医疗模式日益受到关注。这种不断变化的临床格局凸显了在临床实践、产品研发和支付方合作方面进行策略协调以优化患者预后的必要性。

变革性的科学、监管和交付模式变革将重塑特发性肺纤维化患者的治疗研发和护理

特发性肺纤维化 (IPF) 的治疗和护理格局正经历着由科学、监管和给药模式等因素驱动的变革。分子生物学和转化研究的进步正在加深我们对纤维化路径的理解，并有可能发现新的作用机制，从而补充或增强现有的抗纤维化策略。同时，监管机构越来越倾向于采用适应性方法和真实世界证据，以加速开发具有充分机制依据的药物，这正在改变申办者对候选药物进行优先排序和设计临床实验方案的方式。

在医疗服务方面，数位健康工具和远端监测正从先导计画发展成为慢性呼吸系统疾病管理的全面组成部分。这些技术支持早期疗育，能够更密切地监测患者依从性，并促进与支付方进行基于价值的合约谈判。此外，随着报销模式转向基于结果的合约模式，支付方和医疗服务提供者更有奖励在提高患者依从性、减少不利事件和优化治疗方法顺序方面开展合作。这些因素正在汇聚，形成一个更动态的生态系统，在这个系统中，临床创新、监管灵活性和商业策略必须紧密结合，才能实现治疗和卫生经济价值。

对2025年美国关税调整预计对供应链、价格趋势以及特发性肺纤维化（IPF）患者治疗获取途径的累积影响进行全面分析

2025年的贸易政策趋势和关税调整为IPF供应链、药品原料采购以及治疗药物和医疗设备的跨境分销带来了复杂的局面。累积的关税措施可能会增加全球采购的活性药物成分（API）和辅料的投入成本，迫使製造商重新评估其供应商组合和原材料筹资策略。因此，企业可能会采取双重采购、近岸外包或垂直整合等策略，以维持供应的连续性并降低地缘政治波动带来的风险。

除了采购环节，关税带来的成本压力很可能会蔓延至价格谈判和报销讨论。支付者和综合医疗网络可能会更密切地审查成本驱动因素，而製造商将被要求提供可靠的价值和疗效数据，以支持处方集中的定位。同时，分销合作伙伴和专科药房可能会调整合约结构以吸收或转嫁成本上涨，这可能会影响患者的用药途径和依从性计划。因此，在特发性肺纤维化（IPF）领域运营的公司应在其商业风险管理框架内评估关税情景，对其供应链的韧性进行压力测试，并积极与相关人员沟通，以确保患者能够不间断地获得必要的治疗。

详细的细分观点整合了治疗层级、给药途径、分销管道和临床环境等方面的差异，从而驱动商业和临床策略。

细分市场层面的差异化是特发性肺纤维化（IPF）相关人员进行策略决策的基础，需要对治疗层级、给药途径、分销网络和终端用户环境有深入的了解。基于治疗层级，我们分析了抗纤维化药物和免疫抑制剂的现状。抗纤维化药物进一步细分为尼达尼布和Pirfenidone，而免疫抑制剂则进一步细分为糖皮质激素和免疫调节剂。糖皮质激素包括Methylprednisolone和泼尼松，而免疫调节剂包括Azathioprine和Mycophenolate Mofetil。每种药物都有不同的临床特征和耐受性，这些都会影响处方行为。

给药途径的细分，包括吸入、注射和口服药物，会影响患者的依从性、监测需求以及门诊与住院的使用。分销管道的趋势，包括医院药房、线上药房、零售药房和专科药房，决定了治疗方法的配发方式以及与治疗启动和维持相关的支援服务。最终使用者群体涵盖门诊中心、居家医疗机构、医院和专科诊所，每个机构在诊断、肺部復健和复杂治疗管理方面的能力各不相同。整合这些细分观点，有助于相关人员识别临床需求、商业性机会和运作摩擦的交集，从而优先考虑能够改善治疗效果并减轻患者负担的干预措施。

深入的区域性洞察，整合美洲、欧洲、中东和非洲以及亚太地区不同的医疗保健系统、报销框架和就医途径。

区域趋势显着影响特发性肺纤维化（IPF）治疗的临床实践模式、监管预期和商业性路径，因此需要製定能够反映当地医疗保健系统结构和报销环境的策略。在美洲，集中式卓越中心和整合的支付方-服务提供方模式促进了指南推荐疗法的相对快速普及，但都市区之间以及公共和私人支付方之间仍然存在医疗服务获取方面的差异。同时，临床网路和远端医疗的兴起正在改变患者从诊断到专科治疗的过渡过程。

在欧洲、中东和非洲地区，法规结构的多样性和报销体系的不均衡造成了定价和准入条件的复杂性，因此需要差异化的打入市场策略和在地化的证据生成。相关人员通常优先考虑卫生技术评估（HTA）的协调性和真实世界数据的收集，以建立针对特定国家的价值评估材料。在亚太地区，医疗保健的快速现代化、不断扩展的专科医疗能力以及不断发展的国内製造能力正在重塑供应链和商业模式。同时，临床指引采纳在可负担性和时间安排上的差异，要求与当地临床医生和支付者进行有针对性的互动。了解这些区域差异对于制定尊重当地标准并最大限度地提高患者可近性的实施计划至关重要。

关键的公司层面洞察整合了现有优势、新兴创新路径以及通路和服务合作伙伴关係在特发性肺纤维化治疗中日益增长的重要性。

特发性肺纤维化（IPF）治疗领域的竞争格局由成熟的製药公司、新兴生物技术公司和专业分销商组成，它们各自在临床开发、商业化和患者支持方面拥有独特的优势。现有企业拥有生产规模、全球监管经验和广泛的支付方网络，能够加速产品上市和健保报销谈判。同时，新兴生技公司往往发展出差异化的作用机制和标靶治疗组合，以解决尚未明确的生物学通路，从而为策略合作和授权交易创造机会。

分销和服务供应商，例如专科药房和患者支援供应商，正日益成为重要的策略合作伙伴，他们提供的服务能够影响长期治疗的成功，例如用药依从性计划、输液核对和治疗结果追踪。合约研究组织 (CRO) 和真实世界数据 (RWE) 合作伙伴在推动可操作的临床试验执行和核准后数据收集方面也发挥关键作用。在不断变化的竞争格局中，成功的公司需要将临床证据的生成与商业规划相结合，利用伙伴关係弥补能力缺口，并保持灵活性以应对支付方的回馈和新兴的临床见解。

产业领导者面临的可操作的策略挑战，包括如何协调证据产生、供应链韧性、数位健康整合和区域市场进入规划。

为了显着改善特发性肺纤维化 (IPF) 患者的治疗效果，产业领导者必须采取果断行动，将临床创新与永续的医疗服务取得和交付模式相结合。首先，要投资于强有力的证据生成，将随机对照试验数据与真实世界的疗效和安全性终点相结合，以支持与支付方的对话和临床指南的更新。在製定证据策略的同时，也要建立灵活的供应链，制定短期紧急时应对计画并实现供应商的策略多元化，以确保患者能够持续获得治疗，同时降低关税和地缘政治风险。

在营运方面，我们将把数位监测和远端医疗功能整合到我们的商业产品中，以支持患者依从性、及早发现不利事件并评估长期疗效。我们将与专科药局和居家医疗服务提供者合作，简化治疗启动流程，减轻临床医生的行政负担。最后，我们将制定区域市场进入计划，纳入符合各国卫生技术评估要求的价值沟通策略，并儘早与临床意见领袖接洽，以加速指南的采纳。透过落实这些优先事项，领导者可以将科学进步转化为医疗服务和病患体验的实际改善。

一种透明的多来源调查方法，结合了专家访谈、临床文献综合和基于情境的供应链风险分析。

本报告的调查方法结合了多源证据综合、专家临床访谈和严谨的定性分析，以确保提供可靠且可操作的见解。主要研究包括对呼吸系统科医生、临床试验专家、供应链经理和医保报销专家进行结构化访谈，以了解他们对诊断路径、治疗决定因素和营运瓶颈的现场观点。次要研究则利用同侪审查文献、监管指导文件、临床指南和产品专论来检验临床结论和治疗背景。

分析方法结合了定性资料的主题编码和治疗模式及分销管道实践的比较评估。情境分析评估了供应链风险因素和关税相关风险，而相关人员分析则为支付方参与和伙伴关係优先事项提出了建议。在整个过程中，我们强调证据检验和假设的透明记录，以支持临床、商业和政策相关人员做出可靠的决策。

简明扼要的结论强调了整合证据、营运韧性和相关人员之间协作的必要性：这些是把特发性肺纤维化 (IPF) 领域的创新转化为改善病患预后的关键。

总之，特发性肺纤维化领域正步入一个可操作创新阶段，治疗方法进展、不断演进的医疗服务模式以及不断变化的贸易格局相互交织，共同重塑着医疗服务的可及性和治疗结果。对疾病机制的深入理解和新型治疗策略为改变疾病进程提供了切实的机会，但要充分发挥这些潜力，需要各方共同投资于循证医学、增强医疗供应韧性以及以患者为中心的护理模式。积极将临床开发与支付方需求和实际营运情况结合的相关人员，将更有能力将科学进步转化为病患的持续价值。

随着医疗保健格局的不断演变，与临床医生、支付方和服务提供者的持续合作对于完善治疗流程、优化药物支援以及确保公平获得医疗服务至关重要。未来的道路既需要严谨的科学研究，也需要切实可行的商业性方案，并且始终致力于在肺功能、生活品质和系统效率方面取得可衡量的改善。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 利用基因生物标誌物预测治疗反应的精准医疗方法正在兴起
  • 开发吸入式抗纤维化製剂，以改善肺部标靶药物传递和患者耐受性
  • 透过整合真实世界证据数据，改进特发性肺纤维化疾病进展模型与健康经济学评价
  • 针对TGF-β和PDGF路径的抗纤维化联合治疗取得进展，以实现协同效应
  • 将机器学习演算法应用于高解析度CT影像，用于IPF的早期诊断和预后分层。
  • 间质干细胞疗法治疗进行进行性特发性肺纤维化（IPF）肺组织再生的合作临床试验

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章特发性肺纤维化市场（依治疗分类）

  • 抗纤维化药物
    • 尼达尼布
    • Pirfenidone
  • 免疫抑制剂
    • 皮质类固醇
      • Methylprednisolone
      • 强的松
    • 免疫调节剂
      • Azathioprine
      • Mycophenolate Mofetil

第九章特发性肺纤维化药物市场（依给药途径划分）

  • 吸入
  • 注射
  • 口服

第十章特发性肺纤维化市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房
  • 专科药房

第十一章特发性肺纤维化市场（以最终用户划分）

  • 门诊治疗中心
  • 居家医疗机构
  • 医院
  • 专科诊所

第十二章特发性肺纤维化市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章特发性肺纤维化市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国特发性肺纤维化市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • Galapagos NV
    • Novartis AG
    • AstraZeneca PLC
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Bristol-Myers Squibb Company
Product Code: MRR-2A0283E25610

The Idiopathic Pulmonary Fibrosis Market is projected to grow by USD 5.66 billion at a CAGR of 5.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.65 billion
Estimated Year [2025] USD 3.86 billion
Forecast Year [2032] USD 5.66 billion
CAGR (%) 5.64%

A clinical and operational introduction to idiopathic pulmonary fibrosis highlighting diagnostic complexity, therapeutic progress, and evolving care pathways

Idiopathic pulmonary fibrosis (IPF) presents a persistent and complex clinical challenge that demands coordinated advances across diagnosis, therapeutics, and care delivery. Clinicians face hurdles in early identification because symptoms are often nonspecific and overlap with other chronic respiratory conditions, while diagnostic confirmation relies on high-resolution imaging, pulmonary function testing, and multidisciplinary consensus. These diagnostic realities delay initiation of disease-modifying therapies and complicate longitudinal management, increasing the imperative for clearer clinical pathways and improved access to diagnostic resources.

Concurrently, therapeutic evolution has introduced disease-modifying antifibrotics alongside legacy immunomodulatory approaches, reshaping clinical paradigms for slowing fibrosis progression and preserving lung function. Health systems now balance the clinical benefits of newer agents with considerations of tolerability, drug interactions, and long-term adherence. As stakeholders refine treatment algorithms, the field is witnessing greater emphasis on biomarkers, personalized risk stratification, and integrated care models that bridge hospital-based specialty clinics with ambulatory and home-based services. This shifting clinical landscape underscores the need for strategic alignment between clinical practice, product development, and payer engagement to optimize patient outcomes.

Transformative scientific, regulatory, and delivery-model shifts that are reshaping therapeutic development and care for idiopathic pulmonary fibrosis patients

The landscape for IPF care and therapy is undergoing transformative shifts driven by scientific, regulatory, and delivery-model forces. Advances in molecular biology and translational research have sharpened understanding of fibrogenic pathways, creating opportunities for novel mechanisms to complement or enhance existing antifibrotic strategies. At the same time, regulatory agencies are increasingly receptive to adaptive and real-world evidence approaches that shorten development timelines for agents with compelling mechanistic rationale, which in turn changes how sponsors prioritize assets and design pivotal programs.

On the delivery side, digital health tools and remote monitoring are moving from pilot projects into substantive components of chronic respiratory disease management. These technologies support earlier intervention, enable closer adherence monitoring, and facilitate value-based contracting discussions with payers. Additionally, shifts in reimbursement paradigms toward outcomes-based arrangements are incentivizing payers and providers to collaborate on adherence, adverse event mitigation, and optimized sequencing of therapies. Taken together, these forces are creating a more dynamic ecosystem where clinical innovation, regulatory flexibility, and commercial strategy must be tightly coordinated to realize therapeutic and health-economic value.

Comprehensive analysis of the projected cumulative effects of 2025 United States tariff adjustments on supply chains, pricing dynamics, and patient access in IPF care

Trade policy developments and tariff adjustments in 2025 present a complex backdrop for IPF supply chains, drug ingredient sourcing, and cross-border distribution of therapeutics and devices. Cumulative tariff measures can increase input costs for active pharmaceutical ingredients and excipients that are sourced globally, requiring manufacturers to reassess supplier portfolios and raw material procurement strategies. As a result, companies may pursue dual-sourcing, nearshoring, or vertical integration to preserve supply continuity and mitigate exposure to geopolitical volatility.

Beyond procurement, tariff-induced cost pressures can cascade into pricing negotiations and reimbursement dialogues. Payers and integrated delivery networks are likely to scrutinize cost drivers more closely, prompting manufacturers to provide robust value and outcomes data to support formulary positioning. In parallel, distribution partners and specialty pharmacies may adapt contracting structures to absorb or pass through cost increases, influencing patient access pathways and adherence programs. Therefore, firms operating in the IPF space should evaluate tariff scenarios within their commercial risk frameworks, stress test supply chain resilience, and proactively engage stakeholders to preserve uninterrupted patient access to essential therapies.

In-depth segmentation perspective synthesizing therapeutic class, administration route, distribution channel, and care setting distinctions that drive commercial and clinical strategy

Segment-level differentiation underpins strategic decision-making for IPF stakeholders, requiring nuanced understanding of therapeutic classes, administration routes, distribution networks, and end-user settings. Based on therapeutic class, the landscape is studied across Antifibrotics and Immunosuppressants, with Antifibrotics further distinguished by Nintedanib and Pirfenidone and Immunosuppressants further subdivided into Corticosteroids and Immunomodulators; the Corticosteroids segment includes Methylprednisolone and Prednisone while Immunomodulators include Azathioprine and Mycophenolate Mofetil, each presenting distinct clinical profiles and tolerability considerations that influence prescribing behavior.

Route of administration considerations separate inhalation, injectable, and oral modalities, which in turn affect adherence patterns, monitoring requirements, and outpatient versus inpatient utilization. Distribution channel dynamics encompass Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Pharmacies, shaping how therapies are dispensed and what support services accompany treatment initiation and maintenance. End-user segmentation spans Ambulatory Care Centers, Home Healthcare Facilities, Hospitals, and Specialty Clinics, each with varied capacity for diagnostics, pulmonary rehabilitation, and complex therapy management. Integrating these segmentation lenses enables stakeholders to identify where clinical need, commercial opportunity, and operational friction intersect, and to prioritize interventions that reduce patient burden while improving therapeutic outcomes.

Detailed regional insights that reconcile differing healthcare systems, reimbursement frameworks, and access pathways across the Americas, Europe Middle East & Africa and Asia-Pacific

Regional dynamics significantly influence clinical practice patterns, regulatory expectations, and commercial pathways for IPF therapies, requiring strategies that reflect local healthcare system structures and reimbursement environments. In the Americas, concentrated centers of excellence and integrated payer-provider models support relatively rapid uptake of guideline-endorsed therapies, yet access variability persists across urban and rural settings and between public and private payers. Meanwhile, clinical networks and telehealth diffusion are changing how patients navigate from diagnosis to specialty care.

In Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement systems create a mosaic of pricing and access conditions that necessitate differentiated market entry strategies and localized evidence generation. Stakeholders often prioritize health technology assessment alignment and real-world data collection to support country-specific value dossiers. Across Asia-Pacific, rapid healthcare modernization, growing specialty care capacity, and evolving domestic manufacturing capabilities are reshaping supply chains and commercial models, while variable affordability considerations and differing clinical guideline adoption timelines require tailored engagement with local clinicians and payers. Appreciating these regional nuances is essential for developing implementation plans that respect local standards of care and maximize patient access.

Key company-level insights synthesizing incumbent advantages, emergent innovation trajectories, and the rising importance of channel and service partnerships in IPF care

The competitive landscape for IPF encompasses established pharmaceutical sponsors, emerging biotechs, and specialty distributors, each contributing distinct capabilities across clinical development, commercialization, and patient support. Established companies bring scale in manufacturing, global regulatory experience, and broad payer relationships that can accelerate product rollout and reimbursement negotiations. Emerging biotechs, by contrast, often advance differentiated mechanisms or targeted combinations that may address unmet biological pathways and create opportunities for strategic partnerships or licensing transactions.

Channel and service providers such as specialty pharmacies and patient support vendors are increasingly strategic partners, delivering adherence programs, infusion coordination, and outcomes tracking that influence long-term treatment success. Contract research organizations and real-world evidence partners also play critical roles by enabling pragmatic studies and post-approval data collection. As competitive dynamics evolve, successful companies will integrate clinical evidence generation with commercial planning, leverage partnerships to bridge capability gaps, and maintain flexibility to respond to payer feedback and new clinical insights.

Actionable strategic imperatives for industry leaders to synchronize evidence generation, supply resilience, digital care integration, and localized market access planning

Industry leaders must act decisively to align clinical innovation with sustainable access and delivery models if they are to meaningfully improve outcomes for people living with IPF. First, invest in robust evidence generation that pairs randomized controlled data with real-world effectiveness and safety endpoints to support payer dialogues and clinical guideline updates. Complementary to evidence strategy, build flexible supply chains with near-term contingency plans and strategic supplier diversification to mitigate tariff and geopolitical risk while preserving consistent patient access.

Operationally, integrate digital monitoring and remote care capabilities into commercial offerings to support adherence, early adverse event detection, and longitudinal outcomes measurement. Collaborate with specialty pharmacies and home healthcare providers to streamline initiation processes and reduce administrative burden on clinicians. Finally, develop localized market access plans that align value communication with country-specific health technology assessment requirements and engage early with clinical opinion leaders to accelerate guideline adoption. By executing these priorities, leaders can translate scientific progress into tangible improvements in care delivery and patient experience.

Transparent, multi-source research methodology combining expert primary interviews, clinical literature synthesis, and scenario-driven supply chain risk analysis

The research methodology underpinning this report integrates multi-source evidence synthesis, expert clinician interviews, and rigorous qualitative analysis to ensure robust and actionable findings. Primary research included structured interviews with pulmonologists, clinical trial specialists, supply chain managers, and reimbursement experts to capture frontline perspectives on diagnostic pathways, therapeutic decision drivers, and operational bottlenecks. Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical guidelines, and product monographs to validate clinical assertions and therapeutic context.

Analytic methods combined thematic coding of qualitative inputs with comparative assessments of treatment paradigms and distribution channel practices. Scenario analysis was employed to evaluate supply chain exposures and tariff-related risks, while stakeholder mapping informed recommendations on payer engagement and partnership prioritization. Throughout, the approach emphasized triangulation of evidence and transparent documentation of assumptions to support confident decision-making by clinical, commercial, and policy audiences.

Concise conclusion emphasizing the necessity of integrated evidence, operational resilience, and stakeholder collaboration to translate IPF innovations into improved patient outcomes

In conclusion, the idiopathic pulmonary fibrosis landscape is entering a period of pragmatic innovation where therapeutic advances, evolving care delivery models, and shifting trade dynamics converge to redefine access and outcomes. Improved mechanistic understanding and novel therapeutic strategies present genuine opportunities to alter disease trajectories, but realizing that potential demands coordinated investments in evidence, supply resilience, and patient-centric care models. Stakeholders who proactively align clinical development with payer needs and operational realities will be best positioned to translate scientific progress into durable value for patients.

As the ecosystem continues to evolve, continual engagement with clinicians, payers, and service providers will be essential to refine treatment algorithms, optimize adherence support, and ensure equitable access. The pathway forward requires both scientific rigor and pragmatic commercial execution, with a relentless focus on measurable improvements in lung function, quality of life, and system-level efficiencies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of precision medicine approaches using genomic biomarkers to predict treatment response in idiopathic pulmonary fibrosis
  • 5.2. Development of inhaled antifibrotic formulations to improve lung-targeted drug delivery and patient tolerability
  • 5.3. Integration of real-world evidence data to refine IPF disease progression models and health economics assessments
  • 5.4. Advancements in antifibrotic combination therapies targeting TGF-B and PDGF pathways for synergistic efficacy
  • 5.5. Application of machine learning algorithms to high-resolution CT imaging for earlier IPF diagnosis and prognosis stratification
  • 5.6. Collaborative clinical trials investigating mesenchymal stem cell therapies for lung tissue regeneration in progressive IPF

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Idiopathic Pulmonary Fibrosis Market, by Therapeutic Class

  • 8.1. Antifibrotics
    • 8.1.1. Nintedanib
    • 8.1.2. Pirfenidone
  • 8.2. Immunosuppressants
    • 8.2.1. Corticosteroids
      • 8.2.1.1. Methylprednisolone
      • 8.2.1.2. Prednisone
    • 8.2.2. Immunomodulators
      • 8.2.2.1. Azathioprine
      • 8.2.2.2. Mycophenolate Mofetil

9. Idiopathic Pulmonary Fibrosis Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral

10. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Specialty Pharmacies

11. Idiopathic Pulmonary Fibrosis Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Healthcare Facilities
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Idiopathic Pulmonary Fibrosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Idiopathic Pulmonary Fibrosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Idiopathic Pulmonary Fibrosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Boehringer Ingelheim International GmbH
    • 15.3.2. F. Hoffmann-La Roche Ltd.
    • 15.3.3. Gilead Sciences, Inc.
    • 15.3.4. Galapagos NV
    • 15.3.5. Novartis AG
    • 15.3.6. AstraZeneca PLC
    • 15.3.7. Pfizer Inc.
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Johnson & Johnson
    • 15.3.10. Bristol-Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL